|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2019
Anzahl der Publikationen: 1
2019
Doerner, T.; Schulze-Koops, H.; Burmester, G. -R.; Iking-Konert, C.; Schmalzing, M.; Engel, A.; Kaestner, P.; Kellner, H.; Kurthen, R.; Krüger, K.; Rubbert-Roth, A.; Schwenke, H.; Peters, M. A. und Tony, H. -P.
(2019):
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).
In: Clinical and Experimental Rheumatology, Bd. 37, Nr. 6: S. 937-945